CM
NBIX icon

Crestline Management’s Neurocrine Biosciences NBIX Stock Holding History

Crestline Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-18,660
Closed -$1.45M – 241
2017
Q4 		$1.45M Sell
18,660
-44,369
-70% -$3.03M 0.15% 65
2017
Q3 		$3.86M Buy
63,029
+18,371
+41% +$969K 0.54% 23
2017
Q2 		$2.05M Buy
+44,658
New +$2.17M 0.28% 39

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Crestline Management's NBIX Position: Q1 2018 in Review

Crestline Management sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 18,660 shares — an estimated $1.45M sold.

Crestline Management first reported a position in NBIX in Q2 2017 and held it in 3 quarters. The position peaked at $3.86M in Q3 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

  • Crestline Management reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
  • Crestline Management sold 18,660 Neurocrine Biosciences shares in Q1 2018, an estimated $1.45M.
  • Crestline Management first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 3 quarters.
  • Crestline Management's Neurocrine Biosciences position peaked at $3.86M in Q3 2017.
  • 267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Crestline Management's 13F filing for Q1 2018, filed 15 May 2018.